Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine for diverticular disease of the colon and irritable bowel syndrome
2008-004228-22Phase 3Active
- Sponsor
- SOFAR
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) and diverticular disease comparing Mesalazine with Placebo (2 arms). Primary endpoint: Improvement of symptoms. Started May 2009; status: active.
02
Drugs
Salcrozine
03
Conditions
irritable bowel syndrome (IBS)diverticular disease
Beyond the preview
Go deeper on 2008-004228-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004228-22.